NCT04982926: A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: EGFR, HER2
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: For patients without HER2+ breast cancer, they must have solid tumors with EGFR or HER2 aberrations
Exclusions: Patients with non-stable brain metastases

Comments are closed.

Up ↑